bpc-157 ulcerative colitis clinical trial Frontiers Frontiers | Stable Gastric Pentadecapeptide
Description
Surprisingly, some folks may experience signs for up to two years
You may interpret a low response as needing a higher dose when the real issue is that you are not receiving the full dose you intended
Important note: BPC-157 has been studied heavily in animal models
As research continues to evolve, the clinical use of peptides may be another tool for providers to reach for
